Why Is Editas (EDIT) Down 16.9% Since Last Earnings Report?

Core Viewpoint - Editas Medicine reported a wider-than-expected loss in Q2 2025, with shares declining approximately 16.9% since the last earnings report, underperforming the S&P 500 [1][2]. Financial Performance - Editas reported a loss of 63 cents per share in Q2 2025, which was worse than the Zacks Consensus Estimate of a loss of 41 cents, compared to a loss of 82 cents per share in the same quarter last year [2]. - Collaboration and other R&D revenues were $3.6 million in Q2 2025, significantly up from the previous year's figure and exceeding the Zacks Consensus Estimate of $1 million, primarily due to revenue recognition from achieved deliverables [3]. - R&D expenses decreased by 70% to $16.2 million compared to $54.2 million in the prior year, attributed to lower clinical and manufacturing costs following the abandonment of the reni-cel program [4]. - General and administrative expenses were $12.9 million, down 29% year-over-year due to reduced employee-related expenses from a decreased headcount [5]. - Restructuring and impairment charges amounted to $26.1 million in Q2 2025 due to the discontinuation of the reni-cel program, with no such charges recorded in the previous year [5]. - As of June 30, 2025, Editas had cash, cash equivalents, and investments totaling $178.5 million, down from $221 million as of March 31, 2025, with expectations to fund operations into Q2 2027 [6]. Market Sentiment - Estimates for Editas have trended upward over the past month, indicating a potentially positive outlook [7]. - Editas holds a Zacks Rank 3 (Hold), suggesting an expectation of in-line returns in the coming months [9]. Industry Comparison - Editas is part of the Zacks Medical - Biomedical and Genetics industry, where GSK has gained 3.5% over the past month, reporting revenues of $10.67 billion for the last quarter, reflecting a year-over-year increase of 7.2% [11].